MedTrace Logo

Discussing COVID-19 Vaccines in Private Facebook Groups

NCT05422898 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 508

Last updated 2022-06-21

No results posted yet for this study

Summary

As the COVID-19 pandemic persists, a sizable proportion of the U.S. population remains unvaccinated and at high risk of death and serious illness from COVID-19. Vaccine hesitancy, fueled by the proliferation of vaccine misinformation on social media, is one factor contributing to lack of vaccination. Current attempts to overcome vaccine misinformation focus on correcting or debunking falsehoods. Although debunking strategies are important components to any public health campaign, communications must also address rationales for vaccine hesitancy that vary among individuals and communities, and directly address the gist of their concerns in an empathetic, non-judgmental manner. We will conduct a randomized controlled trial to test the effectiveness of empathic, relationship-building interactions relative to standard provision of information on social media to address COVID-19 vaccine hesitancy.

Conditions

Interventions

BEHAVIORAL

Gist messages on COVID-19 vaccination

Participants will receive gist-based messages on COVID-19 vaccines and have their concerns addressed by a group moderator

BEHAVIORAL

COVID-19 vaccine information

Participants will receive a link to the Facebook COVID-19 Information Center via a private Facebook Group

Sponsors & Collaborators

  • George Washington University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-01-17
Primary Completion
2022-04-04
Completion
2022-04-04

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05422898 on ClinicalTrials.gov